デフォルト表紙
市場調査レポート
商品コード
1587471

乳がんリキッドバイオプシー市場規模、シェア、動向分析レポート:循環バイオマーカー別、用途別、地域別、セグメント予測、2025年~2030年

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), By Application, By Region, And Segment Forecasts, 2025 - 2030


出版日
ページ情報
英文 120 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
乳がんリキッドバイオプシー市場規模、シェア、動向分析レポート:循環バイオマーカー別、用途別、地域別、セグメント予測、2025年~2030年
出版日: 2024年10月09日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乳がんリキッドバイオプシー市場の成長と動向:

世界の乳がんリキッドバイオプシー市場規模は2030年に19億米ドルに達すると予測され、2025年から2030年にかけてCAGR 8.5%で成長すると予測されます。

この成長の背景には、非侵襲的手法への嗜好の高まり、早期診断・治療に対する意識の高まり、乳がん有病率の上昇があります。例えば、WHOによると、2020年には世界で68万5000人の女性が乳がんで命を落とし、230万人の女性が乳がんに罹患しています。リキッドバイオプシーは、乳がんを早期に発見するための画期的な技術として示唆されており、これが採用を後押しし、成長に拍車をかけています。

乳がんの有病率の増加に伴い、がんの早期発見と早期治療のための適切な診断ツールの提供が強く求められています。需要の高まりに対応するため、診断分野での研究開発が活発化しています。例えば、2022年6月、BioFluidicaの研究結果によると、HER2陽性乳がん患者は、HER2指向のテーラーメイド治療を受けながら、成功率を上げています。関連分野の開発が進んでいる結果、リキッドバイオプシーの臨床的意義がより知られるようになってきています。これらの技術を広く利用できるようにするためには、さらなる介入臨床試験と、循環バイオマーカーを適切に組み合わせるアルゴリズムの作成が必要です。

非血液悪性腫瘍を同定するための、より低侵襲な技術が、循環バイオマーカーに関する継続的な研究における技術的ブレークスルーの結果として開発されました。従来の腫瘍生検に比べ、リキッドバイオプシーはリアルタイムで患者をモニタリングできる有望な選択肢と考えられています。例えば、2022年4月、Epic Sciences, Inc.は、転移性乳がんの診断のためのリキッドバイオプシー技術に基づく血液検査であるDefineMBCを同社のCLIA検査施設ポートフォリオに加えました。

さらに、この市場で事業を展開する主要企業は、幅広い用途に使用できる製品の拡大と上市に注力しています。例えば、2022年6月、NeoGenomics社の子会社であるInivata Limited社は、ヒト上皮成長因子受容体2(HER2)陰性で、微小残存病変(MRD)と再発を伴う高リスク患者の分析に用いるRaDaRアッセイの新たなデータを発表しました。

乳がんリキッドバイオプシー市場レポートハイライト

  • 循環腫瘍細胞(CTC)セグメントは予測期間中最も速いCAGR 9.4%で成長すると予測されます。早期乳がんにおけるCTCの有用性を特定するための調査が進行中です。
  • 早期発見/スクリーニングセグメントは、がんの早期発見におけるリキッドバイオプシーの使用用途の増加により、予測期間中にCAGR 9.7%の大幅な成長が見込まれています。
  • 用途別では、早期治療の必要性に起因する治療選択分野が2024年に51.5%の最大収益シェアで市場をリードしました。
  • 乳がんリキッドバイオプシー市場は、北米が2024年に44.64%の最大収益シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 乳がんリキッドバイオプシー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 乳がんリキッドバイオプシー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 乳がんリキッドバイオプシー市場:循環バイオマーカーの推定・動向分析

  • セグメントダッシュボード
  • 乳がんリキッドバイオプシー市場:循環バイオマーカーの変動分析
  • 循環バイオマーカー別乳がんリキッドバイオプシー市場の見通し
  • 2018年から2030年までの市場規模と予測および動向分析
    • 循環腫瘍細胞(Ctcs)
    • 循環細胞-遊離DNA(Cfdna)
    • 細胞外小胞(Evs)
    • その他の循環バイオマーカー

第5章 乳がんリキッドバイオプシー市場:用途の推定・動向分析

  • セグメントダッシュボード
  • 乳がんリキッドバイオプシー市場:用途変動分析
  • 乳がんリキッドバイオプシー市場の用途別展望
  • 2018年から2030年までの市場規模と予測および動向分析
    • 早期発見・スクリーニング
    • 診断
    • 治療の選択
    • モニタリング

第6章 乳がんリキッドバイオプシー市場:地域の推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年:
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 市場参入企業の分類
  • 主要市場参入企業による最近の動向と影響分析
  • 主要企業の市場シェア、2024年
  • 主要企業プロファイル
    • The Menarini Group
    • NeoGenomics Laboratories
    • F. Hoffmann-La Roche Ltd.,
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific, Inc.
    • QIAGEN
    • Biocept, Inc.
    • Sysmex Corporation
    • Fluxion Biosciences, Inc.
    • Epic Sciences, Inc.
図表

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 4. Global Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 5. Global Breast Cancer Liquid Biopsy Market, by region, 2018 - 2030 (USD Million)
  • Table 6. North America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 7. North America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 8. U.S. Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 9. U.S. Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 10. Mexico Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 11. Mexico Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 12. Canada Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 13. Canada Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 14. Europe Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 15. Europe Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 16. Europe Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 17. UK Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 18. UK Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 19. Germany Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 20. Germany Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 21. France Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 22. France Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 23. Italy Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 24. Italy Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 25. Spain Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 26. Spain Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 27. Denmark Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 28. Denmark Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 29. Norway Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 30. Norway Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 31. Sweden Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 32. Sweden Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 33. Asia Pacific Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 36. Japan Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 37. Japan Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 38. China Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 39. China Breast Cancer Liquid Biopsy Market, by application 2018 - 2030 (USD Million)
  • Table 40. India Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 41. India Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 42. Australia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 43. Australia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 44. South Korea Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 45. South Korea Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 46. Thailand Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 47. Thailand Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 48. Latin America Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 49. Latin America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 50. Latin America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 51. Brazil Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 52. Brazil Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 53. Argentina Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 54. Argentina Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 55. Middle East & Africa Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 58. South Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 59. South Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 60. Saudi Arabia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 62. UAE Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 63. UAE Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 64. Kuwait Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Breast Cancer Liquid Biopsy Market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Breast Cancer Liquid Biopsy Market, Circulating Biomarkers outlook key takeaways (USD Million)
  • Fig. 12 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers movement analysis (USD Million), 2024 & 2030
  • Fig. 13 Circulating Tumor Cells (Ctcs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Circulating Cell - Free Dna (Cfdna) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Extracellular Vesicles (Evs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Other Circulating Biomarkers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Early Detection/Screening market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Diagnosis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Treatment Selection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Monitoring market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Breast Cancer Liquid Biopsy Market: regional key takeaways (USD Million)
  • Fig. 22 Breast Cancer Liquid Biopsy Market: regional outlook, 2023 & 2030, USD Million
  • Fig. 23 North America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Mexico Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Italy Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Denmark Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Sweden Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 South Korea Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Australia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 List of key emerging company's/liquid biopsy disruptors/innovators
目次
Product Code: GVR-4-68039-991-9

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.90 billion in 2030 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

  • The circulating tumor cells (CTCs) segment is anticipated to grow at the fastest CAGR of 9.4% over the forecast period. There has been ongoing research to specify the utility of CTCs in early-stage breast cancer
  • The early detection/screening segment is expected to grow at a significant CAGR of 9.7% during the forecast period, due to the increasing application of the use of liquid biopsy in the early detection of cancer.
  • Based on application, the treatment selection segments led the market with the largest revenue share of 51.5% in 2024, attributed to the need to provide early treatment
  • North America dominated the breast cancer liquid biopsy market with the largest revenue share of 44.64% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Circulating Biomarkers
    • 1.2.2. Application
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Circulating Biomarkers outlook
    • 2.2.2. Application outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Breast Cancer Liquid Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence Of Breast Cancer
      • 3.2.1.2. Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
      • 3.2.1.3. Need To Provide Early Diagnosis And Treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost Associated With Breast Cancer Liquid Biopsy Tests
      • 3.2.2.2. Regulatory & Reimbursement Hurdles
  • 3.3. Breast Cancer Liquid Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
  • 4.3. Breast Cancer Liquid Biopsy Market by Circulating Biomarkers Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Circulating Tumor Cells (Ctcs)
      • 4.4.1.1. Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.2. Circulating Cell - Free Dna (Cfdna)
      • 4.4.2.1. Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.3. Extracellular Vesicles (Evs)
      • 4.4.3.1. Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.4. Other Circulating Biomarkers
      • 4.4.4.1. Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Breast Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Breast Cancer Liquid Biopsy Market: Application Movement Analysis
  • 5.3. Breast Cancer Liquid Biopsy Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Early Detection/Screening
      • 5.4.1.1. Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Diagnosis
      • 5.4.2.1. Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Treatment Selection
      • 5.4.3.1. Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.4. Monitoring
      • 5.4.4.1. Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Breast Cancer Liquid Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Key company market share, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. The Menarini Group
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. NeoGenomics Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. F. Hoffmann - La Roche Ltd.,
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Myriad Genetics, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. QIAGEN
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Biocept, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Sysmex Corporation
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Fluxion Biosciences, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Epic Sciences, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives